Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Icodec During Exercise and Fasting in Type 2 Diabetes
NCT06288412Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, single-arm trial of insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Time below range, glucose < 3.0 mmol/L within 24 hours after start of exercise. Started Feb 2024; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06288412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288412.